Hepatocellular carcinoma

Journal of Hepatology

Volumn 32, Issue SUPPL.1, 2000, Pages 225-237

  Okuda, Kunio ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Adenomatous hyperplasia; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; DECARBOXYPROTHROMBIN; HEPATITIS B VACCINE; HEPATITIS C VACCINE; LECTIN; POLYPRENOIC ACID;

AFFINITY CHROMATOGRAPHY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE MARKER; EARLY DIAGNOSIS; GENE MUTATION; GENETIC DISORDER; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; INCIDENCE; LIVER NEOPLASMS; PREVENTIVE MEDICINE;

EID: 0034090264     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(00)80428-6     Document Type: Article

References (160)

1. Bosch X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-85.
2. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47: 4967-72.
3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6-29.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50
5. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-3.
6. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998; 351: 214-5.
7. Okuda K. Liver cancer. In: Zuckerman AJ, Thomas HC, editors. Viral hepatitis. Scientific basis and clinical management. Edinburgh: Churchill Livingstone; 1994. p. 269-81.
8. Kew MC, Yu MC, Kedda MA, Coppin A, Sarkin A, Hodkinson J. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997; 112: 184-7.
9. Ikeda K, Saitoh S, Koide I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinoma: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
10. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15: 225-36.
11. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
12. Kew MC. Hepatic tumors and cysts. In: Feldman M, Sleisenter MH, Scharschmidt BF, editors. Sleisenger & Fordtran's gastroenterology and liver disease: pathology/diagnosis/management. 6th edn. Philadelphia: Saunders; 1998. p. 1364-87.
13. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
14. Seeff LB, Buskell-Bales Z, Wright EC, Duraco SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906-11.
15. Seeff LB, Hollinger FB, Later HJ, Wright EC, Bales ZB, NHLBI Study Group. Long-term morbidity of transfusion-associated hepatitis (TAH) C. Hepatology 1998; 28: 407A (abstract).
16. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcome after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.
17. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
18. Davis GL. Hepatitis C. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff's diseases of the liver. 8th edn. Philadelphia: Lippincott-Raven; 1999. p. 793-836.
19. Kenny-Walsh E, for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228-33.
20. Kiyosawa K, Tanaka E, Sodeyama T, Yoshizawa K, Yabu K, Furuta K, et al. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. Gastroenterology 1994; 106: 1596-602.
21. Mori M, Inutsuka H, Wada I, Yamamoto K, Honda M, Naramoto J. Factors associated with hepatitis C virus transmission in the area of high incidence of hepatic cancer in Japan. Hepatol Res 1998; 10: 17-26.
22. Cohen J. The scientific challenge of hepatitis C. Science 1999; 285: 26-30.
23. Okuda K. Hepatitis C virus and hepatocellular carcinoma. In: Okuda K, Tabor E, editors. Liver Cancer. London: Churchill Livingstone; 1997. p. 39-50.
24. Weinberg RA. Oncogenes, antioncogenes and the molecular bases of multistep carcinogenesis. Cancer Res 1989; 49: 3713-21.
25. Sugimura T. Multistep carcinogenesis: a 1992 perspective. Science 1992; 258: 603-7.
26. Fearon ER. Molecular genetics of colorectal cancer. Ann N Y Acad Sci 1995; 768: 101-10.
27. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992; 15: 948-63.
28. Farber E. On the pathogenesis of experimental hepatocellular carcinoma. In: Okuda K, Peters RL, editors. Hepatocellular carcinoma. New York: Wiley; 1976. p. 3-22.
29. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-31.
30. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hot spot in the p53 gene in human hepatocellular carcinoma. Nature 1991; 350: 427-8.
31. Kazachkov Y, Khaoustov V, Yoffe B, Solomon H, Klintmalm GBG, Tabor E. p53 abnormalities in hepatocellular carcinoma from United States patients: analysis of all 11 exons. Carcinogenesis 1996; 17: 2207-12.
32. Hayashi H, Sugio K, Matsumata T, Adachi E, Urata K, Tanaka S, et al. The mutation of codon 249 in the p53 gene is not specific in Japanese hepatocellular carcinoma. Liver 1993; 13: 279-81.
33. Unsal J, Yakicier C, Marçais C, Kew M, Volkmann M, Zentgraf H, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA 1994; 91: 822-6.
34. Challen C, Lunec J, Warren W, Collier J, Bassendine MF. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinoma from Britain. Hepatology 1992; 16: 1362-6.
35. Volkman M, Hofmann WJ, Müller M, Räth U, Otto G, Zentgraf H, et al. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 1994; 9: 195-204.
36. Vesey DA, Hayward HK, Cooksley WGE. p53 gene in hepatocellular carcinoma from Australia. Cancer Detct Prev 1994; 18: 123-30.
37. Park YM, Yoo YD, Paik SY, Kim BS, Tabor E. Mutation of tumor suppressor gene p53 in hepatocellular carcinoma from Korea. Exp Med 1996; 28: 173-9.
38. Sheu J, Huang G, Lee P, Chung JC, Chou HC, Lai MY, et al. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res 1992; 52: 6098-100.
39. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda S. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 1994; 54: 231-5.
40. Schleger C, Becker R, Oesch F, Steinberg P. The human p53 gene mutated at position 249 per se is not sufficient to immortalize human liver cells. Hepatology 1999; 29: 834-8.
41. Ghebranious N, Sell S. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice. Hepatology 1998; 27: 967-73.
42. Sell S, Hunt JM, Dunsford HA, Chisari FV. Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res 1991; 51: 1278-85.
43. Aquilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994; 264: 1317-9.
44. Van Rensburg SJ, Cook-Mozaffari P, Van Schalkwyk DJ, Van Der Watt JJ, Vincent TJ, Purchase IF. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer 1985; 51: 713-26.
45. Chang MH, Chen DS, Hsu HC, Hsu HY, Lee CY. Maternal transmision of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 1989; 64: 2377-80.
46. Chang MH, Hsu HC, Lee CY, Chen DS, Lee CH, Lin KS. Fraternal hepatocellular carcinoma in young children in two families. Cancer 1984; 53: 1807-10.
47. Wu TC, Tong MJ, Hwang B, Les SD, Hu MM. Primary hepatocellular carcinoma and hepatitis B virus infection during childhood. Hepatology 1987; 7: 46-8.
48. Bcaslcy RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan. Lancet 1981; 2: 1129-33.
49. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. J Am Med Assoc 1996; 276: 906-8.
50. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336: 1855-9.
51. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B transgenic mice. Cell 1989; 59: 1145-56.
52. Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990; 50: 3400-7.
53. 1NK4 (MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 1997; 25: 1376-81.
54. De Benedetti VM, Welsh JA, Trivers GE, Horpster A, Parkinson AJ, Lanier AP, et al. p53 is not mutated in hepatocellular carcinoma from Alaska natives. Cancer Epidemiol Biomarkers Prev 1995; 4: 79-82.
55. Su D. Drinking water and liver cancer. An epidemiologic approach to the etiology of this disease in China. Chin Med J 1979; 92: 748-56.
56. Ueno Y, Nagata S, Tsutsumi T, Hasegawa A, Watanabe MF, Park HD, et al. Detection of microcystins, a bluegreen algal hepatotoxin, in drinking water samples in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay. Carcinogenesis 1996; 17: 1317-21.
57. Yu S-Z. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10: 674-82.
58. Popper H. Viral versus chemical hepatocarcinogenesis. J Hepatol 1988; 6: 226-38.
59. Popper H, Shih JWK, Gerin JL. Woodchuck hepatitis and hepatocellular carcinoma. Hepatology 1981; 1: 91-8.
60. Tiollais P, Hsu TY, Möröy T, Etiemble J, Fourel G, Thé, et al. Hepadnaviruses as insertional mutagens in hepatocellular carcinoma. In: Tabor E, diBisceglie AM, Purcell RH, editors. Etiology, pathology and treatment of hepatocellular carcinoma in North America. Woodlands TX: Portofolio Publ Co.; 1991. p. 147-58.
61. Matsubara K, Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med 1990; 70: 243-60.
62. Yen TSB. Hepadnaviral X protein: review of recent progress. J Biomed Sci 1996; 3: 20-30.
63. Hsieh C, Nakashima Y, Tabor E. Deletion mutations of the hepatitis B virus x gene in human hepatocellular carcinoma. Biochen Biophys Res Commun 1997; 241: 726-9.
64. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBX gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-20.
65. Saxena R, Ye MQ, Emre S, Klion F, Malesnik MA, Thung SN. De novo hepatocellular carcinoma in a hepatic allograft with recurrent hepatitis C cirrhosis. Liver Transpl Surg 1999; 5: 81-2.
66. Koike K, Moriya K, Ishibashi K, Matsuura Y, Suzuki T, Saito I, et al. Expression of hepatitis C virus envelope proteins in transgenic mice. J Gen Virol 1995; 76: 3031-8.
67. Takcgami T, Hasumura Y. The difference in immunogenicity among the regions of hepatitis C virus nonstructural protein NS3. Acta Hepatol Jpn 1993; 34: 343-4.
68. Sakamoto D, Furukawa T, Takegami T. Hepatitis C virus non-structural protein NS3 transforms NIH 3T3 cells. J Virol 1995; 69: 3893-6.
69. Ray RB, Lagging LM, Meyer K, Steele R, Ray R. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995; 37: 209-20.
70. Kim DW, Suzuki R, Harada T, Saito I, Miyamura T. Transsuppression of gene expression by hepatitis C viral core protein. Jpn J Med Sci Biol 1994; 47: 211-20.
71. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, et al. Hepatitic C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78: 1527-31.
72. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Med 1998; 4: 1065-7.
73. Kojiro M, Sugihara S, Nakashima O. Pathomorphologic characteristics of early hepatocellular carcinoma. In: Okuda K, Tobe T, Kitagawa T, editors. Early detection and treatment of liver cancer. Gann monograph on cancer research. No. 38. Tokyo: Jpn Sci Soc Press; 1991. p. 29-38.
74. Arakawa M, Kage M, Sugihara S, Nakashima T, Suenaga M, Okuda K. Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver. Observations in five cases. Gastroenterology 1986; 91: 198-208.
75. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991; 22: 172-8.
76. Wada K, Kondo F, Kondo Y. Large regenerative nodules and dysplastic nodules in cirrhotic livers: a histopathologic study. Hepatology 1988; 8: 1684-8.
77. Kondo F, Hirooka N, Waka K, Kondo Y. Morphologic clues for the diagnosis of small hepatocellular carcinomas. Virchows Arch A 1987; 411: 15-21.
78. Kondo F, Ebara M, Sugiura N, Wada K, Kita K, Hirooka N, et al. Histological features and clinical course of large regenerative nodules: evaluation of their precancerous potentiality. Hepatology 1990; 12: 592-8.
79. Terasaki S, Kaneko S, Kobayashi K, Nonomura A, Nakanuma Y. Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. Gastroenterology 1998; 115: 1216-22.
80. Nakano M, Saito A, Yamamoto M, Doi M, Takasaki K. Stromal and blood vessel wall invasion in well-differentiated hepatocellular carcinoma. Liver 1997; 17: 41-6.
81. Nakashima O, Sugihara S, Kage M, Kojiro K. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 1995; 22: 101-5.
82. Kanai T, Hirohashi S, Upton MP, Noguchi M, Kishi K, Makuuchi M, et al. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer 1987; 60: 810-9.
83. Hirooka N, Nitta Y, Tsunoda T, Kitazawa E, Sato J, Machii A, et al. Microscopic incipient hepatocellular carcinoma found incidentally in a routine liver biopsy specimen. Hepatology 1990; 12: 291-4.
84. Member of the working party. Terminology of chronic hepatitis, hepatic allograft rejection, and nodular lesions of the liver: summary of recommendations developed by an international working party, supported by the World Congress of Gastroenterology, Los Angeles, 1994. Am J Gastroenterol 1994; 89: S177-81.
85. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 17: 27-35.
86. Kemney F, Vadrot J, Wu A, Smadja C, Meakins JL, Franco D. Morphological and histological features of resected hepatocellular carcinoma in cirrhotic patients in the West. Hepatology 1989; 9: 253-7.
87. Theise NS, Schwartz M, Miller C, Thung SN. Macroregenerative nodules and hepatocellular carcinoma in forty-one sequential adult liver explants with cirrhosis. Hepatology 1992; 16: 949-55.
88. Mion F, Grozel L, Boillot O, Paliard P, Berger F. Adult cirrhotic liver explants: precancerous lesions and undetected small hepatocellular carcinomas. Gastroenterology 1996; 111: 1587-92.
89. Bhattacharya S, Dhillon AP, Rees J, Savage K, Saada J, Burrhoughs A, et al. Small hepatocellular carcinoma in cirrhotic explant livers: identification by macroscopic examination and lipiodol localization. Hepatology 1997; 25: 613-7.
90. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Okazaki N, Takayasu K, et al. Malignant transformation of adenomatous hyperplasia to hepatocelluar carcinoma. Lancet 1990; 336: 1150-3.
91. Borzio M, Bruno S, Toncalli M, Mels C, Remella G, Borzio F, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis; a prospective study. Gastroenterology 1995; 108: 812-7.
92. Borzio M, Borzio F, Croce A, Sala M, Salmi A, Leandro G, et al. Ultrasonography-detected macroregenerative nodules in cirrhosis: a prospective study. Gastroenterology 1997; 112: 1617-23.
93. Nakashima Y, Nakashima O, Hsia CC, Kojiro M, Tabor E. Vascularization of small hepatocellular carcinoma: correlation with differentiation. Liver 1999; 19: 12-8.
94. Ueda K, Terada T, Nakanuma Y, Matsui O. Vascular supply in adenomatous hyperplasias of the liver and hepatocellular carcinoma: a morphometric study. Hum Pathol 1992; 23: 619-26.
95. Matsui O, Kadoya M, Yoshikawa J, Kameyama T, Takashima T, Nakamura Y, et al. Benign and malignant nodules in cirrhotic liver: distinction in bases on blood supply. Radiology 1991; 178: 493-7.
96. Nakanuma Y, Hirata K, Terasaki S, Ueda K, Matsui O. Analytical histopathological diagnosis of small hepatocellular nodules in chronic liver disease. Histol Histopathol 1998; 13: 1077-87.
97. Eguchi A, Nakashima O, Okudaira S, Sugihara S, Kojiro M. Adenomatous hyperplasia in the vicinity of small hepatocellular carcinoma. Hepatology 1992; 15: 843-8.
98. Tsuda H, Hirohashi S, Shimosato Y, Terada M, Hascgawa H. Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma. Gastroenterology 1988; 95: 1664-6.
99. Aihara T, Noguchi S, Sasaki Y, Nakano H, Imaoka S. Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis. Gastroenterology 1994; 107: 1805-11.
100. Kawai S, Imazeki F, Yokosuka O, Shiina S, Kato N, Omata M. Clonality in hepatocellular carcinoma: analysis of methylation pattern of polymorphic X-chromosome-linked phosphoglucerate kinase gene in females. Hepatology 1995; 22: 112-7.
101. Aihara T, Noguchi S, Sasaki Y, Nakano H, Monden M, Imaoka S. Clonal analysis of precancerous lesion of hepatocellular carcinoma. Gastroenterology 1996; 111: 455-61.
102. Paradis V, Laurendeau I, Vidaud M, Bedossa P. Clonal analysis of macronodules in cirrhosis. Hepatology 1998; 28: 953-8.
103. Theise ND. Cirrhosis and hepatocellular neoplasia: more like cousins than like parent and child. Gastroenterology 1996; 111: 526-8.
104. Lieberman H, Furie BC, Tong MJ, Blanchard RA, Lo K-J, Lee S-D. Des-y-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427-31.
105. Motohara K, Kuroki Y, Kan H, Endo F, Matsuda I. Detection of vitamin K deficiency by use of an enzyme-linked immunosorbent assay for circulating abnormal prothrombin. Pediatr Res 1985; 19: 354-7.
106. Okuda H, Obata H, Nakanishi T, Furukawa R, Hashimoto E. Production of abnormal prothrombin (des-γ-carboxy prothrombin) by hepatocellular carcinoma: a clinical study. J Hepatol 1987; 4: 347-63.
107. Okuda H, Nakanishi T, Furukawa M, Obata H. Vitamin K-dependent proteins and hepatocellular carcinoma. J Gastroenterol Hepatol 1991; 6: 392-9.
108. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Watanabe K, et al. Measurement of serum levels of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immuno-assay kit with increased sensitivity. Cancer 1999; 85: 812-8.
109. Kuromatsu H, Tanaka M, Simauchi Y, Shimada M, Tanikawa K, Watanabe K. Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellualr carcinoma. J Gastroenterol 1997; 32: 507-12.
110. Okuda K, Kojiro M. Small hepatocellular carcinoma. In: Okuda K, Ishak KG, editors. Neoplasms of the liver. Tokyo: Verlag; 1987. p. 215-26.
111. Okuda K. Clinical aspects of hepatocellular carcinoma-analysis of 134 cases. In: Okuda K, Peters RL, editors. Hepatocellular carcinoma. New York: Wiley; 1976. p. 387-436.
112. Breborowicz J, Mackiewiz A, Breborowiza D. Micro-heterogeneity of α-fetoprotein in patient serum as demonstrated by lectin affinity-electrophoresis. Scand J Immunol 1981; 14: 15-20.
113. Aoyagi Y, Suzuki Y, Isemura M, Soga K, Ozaki T, Ichida T, et al. Differential reactivity of α-fetoprotein with lectins and evaluation of its usefulness in the diagnosis of hepatocellular carcinoma. Gann 1984; 75: 809-15.
114. Taketa K, Ichikawa E, Tage H, Hirai H. Antibody-affinity blotting, a sensitive technique for the detection of α-fetoprotein separated by lectin affinity electrophoresis in agarose gels. Electrophoresis 1985; 6: 492-7.
115. Taketa K, Hirai H. Lectin affinity electrophoresis of alpha-fetoprotein in cancer diagnosis. Electrophoresis 1989; 10: 562-7.
116. Aoyagi Y, Isematsu M, Suzuki Y, Sekine C, Soga K, Ozaki T, et al. Fucosylated α-fetoprotein as a marker of early hepatocellular carcinoma. Lancet 1985; 2: 1353-4.
117. Rimal N, Ikeda S, Taketa K, Kariya T. Mass screening for early detection of hepatocellular carcinoma by setting a high-risk population with α-fetoprotein and its glycoforms. Hepatol Res 1997; 9: 9-19.
118. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993; 328; 1802-6.
119. Tagawa M, Omata M, Ohto M. Nucleotide sequence of prothrombin gene in abnormal prothrombin-producing hepatocellular carcinoma cell lines. Cancer 1992; 69: 643-7.
120. Matsumura M, Niwa Y, Kato N, Komatsu Y, Shina S, Kawabe T, et al. Detection of α-fetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma in the circulation: a possible predictor of metastatic hepatocellular carcinoma. Hepatology 1994; 20: 1418-25.
121. Komeda T, Fukuda Y, Sando T, Kita R, Furukawa M, Nishida N, et al. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood. Cancer 1995; 75: 2214-9.
122. Nambu S, Nishimori H, Sasaki M, Higuchi K, Watanabe A. α-fetoprotein messenger RNA in peripheral blood as a marker of circulating hepatocellular carcinoma cells. Int Hepatol Commun 1995; 3: 217-21.
123. Nambu S, Nishimori H, Maekawa M, Higuchi K, Watanabe A. Plasma PIVKA-II values as an indicator of AFP mRNA in the circulation in patients with advanced hepatocellular carcinoma. Hepatol Res 1997; 8: 28-36.
124. 2 microbubbles. Radiology 1986; 161: 701-5.
125. Takada T, Yasuda H, Uchiyama K, Hasegawa H, Shikata J. Contrast-enhanced intraoperative ultrasonography of small hepatocellular carcinomas. Surgery 1990; 107: 528-32.
126. 2 microbubbles. Radiology 1992; 182: 155-60.
127. Nomura Y, Matsuda Y, Yabuuchi I, Nishioka M, Tarui S. Hepatocellular carcinoma in adenomatous hyperplasia. Detection with contrast-enhanced US with carbon dioxide microbubbles. Radiology 1993; 187: 353-6.
128. Kudo M, Tomita S, Tochio H, Miura J, Okabe Y, Hirasa M, et al. Sonography with intraarterial infusion of carbon dioxide microbubbles (sonographic angiography): value in differential diagnosis of hepatic tumors. Am J Roentgenol 1992; 158: 65-74.
129. Kudo M, Tomita S, Tochio H, Kashida H, Hirasa M, Todo A. Hepatic focal nodular hyperplasia: specific findings at dynamic contrast-enhanced US with carbon dioxide microbubbles. Radiology 1991; 179: 377-82.
130. Goldberg BB, Hilpert PL, Burns PN, Liu JB, Newman LM, Merton DA, et al. Hepatic tumors: signal enhancement at Doppler US after intravenous injection of a contrast agent. Radiology 1990; 177: 713-7.
131. Kudo M. Ultrasound diagnosis. In: Okuda K, Tabor E, editors. Liver cancer. London: Churchill Livingstone; 1997. p. 331-46.
132. Tanaka S, Kitamura T, Fujita M, Kasugai H, Inoue A, Ishiguro S. Small hepatocellular carcinoma. Differentiation from adenomatous hyperplastic nodule with color Doppler flow imaging. Radiology 1992; 182: 161-5.
133. Tanaka S, Kitamura T, Fujita M, Nakanishi K, Okuda S. Color Doppler flow imaging on liver tumors. Am J Roentgenol 1990; 143: 509-14.
134. Koito K, Namieno T, Morita K. Differential diagnosis of small hepatocellular carcinoma and adenomatous hyperplasia with power Doppler sonography. Am J Roentgenol 1998; 170: 157-61.
135. Kudo M. Imaging diagnosis of hepatocellular carcinoma and premalignant boderline lesions. Semin Liver Dis 1999; 19 (in press).
136. Yumoto Y, Jinno K, Tokuyama K, Arakai Y, Ishimitsu T, Maeda H, et al. Hepatocellular carcinoma detected by iodized oil. Radiology 1985; 154: 19-24.
137. Ohnishi H, Hirai T, Yamada R, Hirohashi S, Honda N, Sakaguchi H, et al. Power Doppler sonography for assessment of the therapeutic effects and recurrence of hepatocellular carcinoma after transcatheter arterial embolization. Ultrasound International 1997; 3: 119-26.
138. Fujimoto M, Moriyasu F, Nishikawa K, Nada T, Okuma M. Color Doppler sonography of hepatic tumors with a galactose-based contrast agent. Correlation with angiographic findings. Am J Roentgenol 1994; 163: 1099-104.
139. Kim AY, Choi BI, Kim TK, Han JK, Yun EJ, Lee KY, et al. Hepatocellular carcinoma: power Doppler US with a contrast agent-preliminary results. Radiology 1998; 209: 135-40.
140. Prando A, Wallace S, Bernardino MR, Lindell MM Jr. Computed tomographic arteriography of the liver. Radiology 1979; 130: 697-701.
141. Masui O, Kadoya M, Suzuki M, Inoue K, Itoh H, Ida M, Takashima T. Dynamic sequential computed tomography during arterial portography in the detection of hepatic neoplasms. Radiology 1983; 146: 721-7.
142. Takayasu K, Okuda K. Imaging in liver disease. Oxford: Oxford Univ Press; 1997. p. 415-23.
143. Ueda K, Matsui O, Kawamori Y, Nakanuma Y, Kadoya M, Yoshikawa J, et al. Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 1998; 206: 161-6.
144. Sugiura N, Takara K, Ohto M, Okuda K, Hirooka N. Treatment of hepatocellular carcinoma by injection of ethanol under ultrasound guidance. Acta Hepatol Jpn 1983; 24: 920 (abstract, in Japanese).
145. Ebara M, Ohto M, Sugiura N, Kita K, Yoshikawa M, Okuda K, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 1990; 5: 616-26.
146. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101-8.
147. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998; 27: 67-72.
148. Sato M, Watanabe Y, Ueda S, Iseki S, Abe Y, Sato N, et al. Microwave coagulation therapy for hepatocellular carcinoma. Gastroenterology 1996; 110: 1507-14.
149. Rossi S, Di Stasi M, Buscarini E, Cavanna I, Quaretti P, Squassante E, et al. Percutanous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1995; 1: 73-81.
150. Goldberg SN, Gazelle GS, Solbiati L, Livraghi T, Tanabe KK, Hahn PF, et al. Ablation of liver tumors using percutaneous RF therapy. Am J Roentgenol 1998; 170: 1023-8.
151. Takayasu K, Muramatsu Y, Moriyama N, Hasegawa H, Makuuchi M, Okazaki N, et al. Clinical and radiological assessment of the results of hepatectomy for small hepatocellular carcinoma and therapeutic arterial embolization for postoperative recurrence. Cancer 1989; 64: 1848-53.
152. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 1997; 26: 108S-11.
153. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.
154. Sugiura N, Sakai Y, Ebara M, Fukuda H, Yoshikawa M, Saisho H, et al. Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: clinical study of 26 cases. J Gastroenterol Hepatol 1996; 11: 535-9.
155. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1997; 24: 141-7.
156. Nishigishi S, Kuroki T, Nakatnai S, Morimoto H, Takeda T, Nakajima S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
157. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995; 76: 743-9.
158. Everson CT, Jensen DM, Draig JR, VanLeeusen DJ, Bain VG, Ehrinpreis MN, et al. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhosis, fibrosis, or nonfibrosis. Hepatology 1999; 30: 271-6.
159. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334: 1561-7.
160. Muto Y, Moriwaki H, Saito A. Prevention of second primary primary tumors by an acyclic retionoid in patients with hepatocellular carcinoma (letter). N Engl J Med 1999; 340: 1046-7.